Navigation Links
Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
Date:10/11/2007

KENILWORTH, N.J., Oct. 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has received approval from the European Commission for its planned acquisition of Organon BioSciences, N.V. from Akzo Nobel N.V., as announced March 12.

Organon BioSciences is comprised mainly of Organon, the human pharmaceutical business, and Intervet, the animal health business. It also includes Nobilon, the human vaccine development unit, and Diosynth, the third- party manufacturing unit of Organon.

In connection with the clearance, Schering-Plough has agreed to divest certain animal health products in Europe. The divestitures are not material to the company's financial results. No divestitures of human health products are required.

Schering-Plough still needs to secure certain regulatory approvals, including clearance from the U.S. Federal Trade Commission (FTC), and continues to expect the transaction to be completed by year-end 2007.

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's plans and future actions and the expected timelines. Forward-looking statements relate to expectations or forecasts of future events. Schering- Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering- Plough's forward-looking statements, including obtaining regulatory approvals, inaccurate assumptions, market forces, economic factors, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A, "Risk Factors" in the company's second quarter 2007 10-Q.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... ... the election of Paul Hermes, Entrepreneur in Residence at Medtronic, Inc., to serve ... developed a proprietary, tissue-engineered scaffold for anterior cruciate ligament (ACL) reconstruction that is ...
(Date:9/20/2017)... Baltimore, MD (PRWEB) , ... September 20, 2017 ... ... for digital pathology, and Huron Digital Pathology , a provider of whole ... Association’s 2017 Pathology Visions conference . The workshop, entitled “Successfully Deploying a Best-in-Class ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... and accurately automates the most dangerous step of sample prep for metals digestion—the ... to provide automation at an affordable price. The system is ideal for any ...
(Date:9/19/2017)... ... September 19, 2017 , ... One of ... to be eliminated, said Lyle Probst, President, CEO and Founder of ExcitePCR ... than other pathogen detection solutions, Probst said, “Sample preparation takes place inside our ...
Breaking Biology Technology:
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):